Last reviewed · How we verify
Citicholine
At a glance
| Generic name | Citicholine |
|---|---|
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Improving Sleep and AD Biomarkers (NA)
- Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct (PHASE1, PHASE2)
- Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma (NA)
- A Brain-Computer Interface-Based Attention Training Program Compared With Methylphenidate and Citicoline
- Evaluation of the Impact of a Nutritional Formulation on Cognitive Performance Following Stress Exposure. (NA)
- Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin (NA)
- Improving Sleep and Cognition in Alzheimer's Disease (NA)
- Citicoline in Youth Alcohol Use Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Citicholine CI brief — competitive landscape report
- Citicholine updates RSS · CI watch RSS
- Ain Shams University portfolio CI